| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04379492 Details | 2020-10-30 Interventional | 2 | 0 | Hydroxychloroqu… COVID-19 COVID19 SARS-Cov-2 Sars-CoV2 | Emerging evidence does not support the use of HCQ for treatment or prevention of SARS -CoV2
infection. No pts have been enrolled. - | |||
| NCT02802514 Details | 2020-10-30 Interventional | 4 | 5 | Exenatide Glucagon-Like P… rGLP-1 protein Nausea Diabetes Mellit… | - - | |||
| NCT02793154 Details | 2020-10-30 Interventional | 4 | 4 | Exenatide rGLP-1 protein Diabetes Mellit… Diabetes Mellit… | Early termination due to insufficient enrollment. - | |||
| NCT02757391 Details | 2020-10-30 Interventional | 1 | 1 | Aldesleukin Cyclophosphamid… Immunologic Fac… Immunomodulatin… Interleukin-2 Pembrolizumab Adenocarcinoma Carcinoma Cholangiocarcin… Colorectal Neop… Esophageal Neop… Stomach Neoplas… Colorectal Aden… Metastatic Chol… Metastatic Colo… Metastatic Dige… Metastatic Esop… Metastatic Gast… Metastatic Panc… Stage IV Colore… Stage IV Esopha… Stage IV Gastri… Stage IV Pancre… Stage IVA Color… Stage IVB Color… | Study halted prematurely and will not resume; participants are no longer being examined or
receiving intervention. - | |||
| NCT01668654 Details | 2020-10-30 Interventional | 3 | 4 | Ezogabine Epilepsy Lennox Gastaut … | FDA placed a clinical hold on the Pediatric Program requiring retigabine discontinuation in
subjects; early termination allows for timely reporting of results. This study was terminated early and only 4 of the planned 500 participants were enrolled. Due to the early study termination and small sample size, many planned analyses were not completed therefore lmiited results data were available. | |||
| NCT01195779 2010-020312-12 Details | 2020-10-30 Interventional | 2 | 4 | Vaccines Influenza, Huma… Influenza Influenza Vacci… | The study was terminated for logistic reasons not related to safety or efficacy of the vaccine. - | |||
| NCT01114503 2009-016747-19 Details | 2020-10-30 Interventional | 2 | 2 | Methylprednisol… Methylprednisol… Methylprednisol… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Eye Diseases Graves Ophthalm… | Clinical study in Graves' ophthalmopathy terminated until there is a better understanding of an
efficacious dose with Otelixizumab from other clinical studies. The study was terminated due to the need of better understanding of an efficacious dose with otelixizumab from other clinical studies. | |||
| NCT00206375 Details | 2020-10-30 Interventional | 4 | 16 | Hormones Hypothyroidism | - - | |||
| NCT04363866 Details | 2020-10-29 Interventional | 2 | 0 | Hydroxychloroqu… COVID-19 SARS-CoV-2 | discontinued in favor of more promising directions that may benefit patients - | |||
| NCT04274933 2019-003452-36 Details | 2020-10-29 Interventional | 1 | 4 | Capecitabine Venetoclax Breast Neoplasm… Disease Progres… Breast Cancer Cancer | Company Decision - | |||
| NCT01987596 Details | 2020-10-29 Interventional | 3 | 23 | Lenograstim Choroid Plexus … Medulloblastoma Neuroblastoma Neuroectodermal… Neuroectodermal… Osteosarcoma Pinealoma Retinoblastoma Sarcoma Wilms Tumor Childhood Choro… Childhood Medul… Childhood Pineo… Childhood Soft … Childhood Supra… Recurrent/Refra… Unspecified Chi… Wilms Tumor and… | - - | |||
| NCT04088903 Details | 2020-10-28 Interventional | 1 | 0 | Daratumumab Allosensitizati… Heart Transplan… | Protocol changed to use subcutaneous rather than intravenous daratumumab. - | |||
| NCT01355575 2010-021515-17 2010-021515-17 Details | 2020-10-28 Interventional | 4 | 15 | Rifaximin Fatty Liver Liver Diseases Non-alcoholic F… NAFLD Nonalcoholic Fa… Nonalcoholic St… | Primary endpoint data review concluded no further patients required. - | |||
| NCT04371406 2020-001702-35 Details | 2020-10-27 Interventional | 3 | 0 | Azithromycin Hydroxychloroqu… COVID-19 Covid-19 | Regulatory approvals have not been obtained - | |||
| NCT01673386 Details | 2020-10-27 Interventional | 2 | 58 | Sunitinib Tivozanib Carcinoma Carcinoma, Rena… Metastatic Rena… | Sponsor The Sponsor terminated Study AV-951-12-205 before enrollment was completed, following the negative decision of the US FDA. | |||
| NCT04344288 2020-001553-48 Details | 2020-10-26 Interventional | 2 | 11 | Prednisone COVID-19 Pneumonia Pneumonia, Vira… Viral Pneumonia… | Competent Authority's decision - | |||
| NCT04231864 Details | 2020-10-26 Interventional | 2 | 0 | Antibodies, Mon… Durvalumab Immunoglobulin … Immunoglobulins Carcinoma Epstein-Barr Vi… Nasopharyngeal … Recurrence Epstein-Barr Vi… Metastatic Naso… Recurrent Nasop… Stage III Nasop… Stage IV Nasoph… Stage IVA Nasop… Stage IVB Nasop… | Feasibility - | |||
| NCT03526536 Details | 2020-10-26 Interventional | 4 | 40 | Insulin Insulin, Globin… Insulin Resista… Kidney Failure,… Diabetes Mellit… End-Stage Renal… | The study required more participants than anticipated for statistical significance. - | |||
| NCT02418754 NCT02603484 Details | 2020-10-26 Interventional | 2 | 505 | Aflibercept Macular Degener… Wet Macular Deg… Neovascular Age… | No additional efficacy seen with REGN2176-3 over aflibercept alone - | |||
| NCT02189889 Details | 2020-10-23 Interventional | 1/2 | 5 | Ferrosoferric O… Anemia Cardiovascular … Cardiovascular … | Initial patients were seen at St Paul Hospital. Enrollment changes occurred with the move to
Clements Hospital. We were unable to identify an infusion room at CUH despite an exhaustive
search for alternatives and forced to terminate early. Early termination leading to small numbers of subjects analyzed. |